STT FA Bio 'GID' GI DYNAMICS
Developer and marketer of EndoBarrier®, a breakthrough device that represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S.
Revenue increased to approximately US$0.5 million for the 3rd Quarter compared to approximately US$0.1 million for the same period last year. The increase in the Company’s revenue in the Quarter was primarily a result of a 163% increase in revenue from sales in Europe and revenue from sales in the Middle East with no corresponding sales in the same period last year.
GI Dynamics is conducting a pivotal clinical trial of EndoBarrier (the ENDO Trial) in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese.
GI Dynamics Announces EndoBarrier® Therapy Data to be Presented at International Diabetes Foundation World Diabetes Conference December 3, 2013.
Has cash of $44m in the bank
I'm expecting a turn around in the SP as this company move forward.
- Forums
- ASX - Short Term Trading
- short term trading week stating 25th nov
short term trading week stating 25th nov, page-40
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online